Skip to main content
Article thumbnail
Location of Repository

Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy

By Shohrat Annaberdyev, Joseph Gibbons and Jeffrey M Hardacre

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec®; Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic and adjuvant settings. We report the case of a 61-year old man who was treated with neoadjuvant imatinib for a massive gastric GIST with the hope of avoiding a potential multi-visceral resection

Topics: Case Report
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2661077
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2002). Antman KH: Imatinib mesylate – a new oral targeted therapy.
    2. (2007). Antonescu CR: Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg
    3. (2007). Casali PG: Surgery of residual disease following moleculartargeted therapy with Imatinib mesylate in advanced/metastatic GIST. Ann Surg
    4. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    5. (2007). Feig BW: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol
    6. (2001). GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
    7. (2004). I: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet
    8. (2002). Kindblom LG: The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors.
    9. (1998). M: CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol
    10. (2002). Pazdur R: Approval Summary: Imatinib mesylate in the treatment of metastatic and/ or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.